Anika Therapeutics - ANIK Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIK shares.
View ANIK analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they expect the company's share price to reach $28.50 in the next twelve months. This suggests that the stock has a possible downside of 10.5%.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.

Anika Therapeutics' stock was trading at $29.60 at the beginning of the year. Since then, ANIK stock has increased by 7.6% and is now trading at $31.84.
View the best growth stocks for 2023 here.

Anika Therapeutics saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 542,800 shares, a decrease of 17.3% from the December 31st total of 656,200 shares. Based on an average daily trading volume, of 101,400 shares, the short-interest ratio is currently 5.4 days. Approximately 3.8% of the company's stock are sold short.
View Anika Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our ANIK earnings forecast.

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.13. The biotechnology company had revenue of $40.26 million for the quarter, compared to analyst estimates of $36.56 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.49% and a negative net margin of 10.33%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.33%), Assenagon Asset Management S.A. (0.33%), Ziegler Capital Management LLC (0.13%), Riverwater Partners LLC (0.07%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIK stock can currently be purchased for approximately $31.84.

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $465.18 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($1.09) on an earnings per share basis.

The company employs 297 workers across the globe.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.